Two-segment structure comprising the Active Pharmaceutical Ingredients Sales Business and the Pharmaceutical Manufacturing and Marketing Business
First written in FY2018. 14 of 15 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「Centered on the Company, a pure holding company, the Group has two reportable segments: the API sales business and the pharmaceutical manufacturing and marketing business.」
The Company reconfirmed the two-reportable-segment structure comprising the API sales business and the pharmaceutical manufacturing and marketing business. - FY2024-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies) during the cumulative third quarter of the fiscal year. There were also no changes among the major affiliated companies.」
The Company reported no material changes in its business activities or major affiliated companies, reconfirming its existing business structure centered on two segments. - FY2024-Q2RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies) during the cumulative second quarter of the fiscal year. There were also no changes among the major affiliated companies.」
The Company reported no material changes in its business activities or major affiliated companies, reconfirming its existing business structure centered on two segments. - FY2024-Q1RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies) during the cumulative first quarter of the fiscal year. There were also no changes among the major affiliated companies.」
The Company reported no material changes in its business activities or major affiliated companies, reconfirming its existing business structure. - FY2023-Q2RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies) during the cumulative second quarter of the fiscal year.」
The Company reported no material changes in its business activities. It also stated that KoA Pharmaceutical Co., Ltd. ceased to exist following its absorption-type merger with KoA Biotech Bay Co., Ltd. in the pharmaceutical manufacturing and marketing business. - FY2023-Q1RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies) during the cumulative first quarter of the fiscal year.」
The Company reported no material changes in its business activities, reconfirming its existing business structure. - FY2022-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies) during the cumulative third quarter of the fiscal year. There were also no changes among the major affiliated companies.」
The Company reported no material changes in its business activities or major affiliated companies, reconfirming its existing business structure. - FY2022-Q2RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies) during the cumulative second quarter of the fiscal year. There were also no changes among the major affiliated companies.」
The Company reported no material changes in its business activities or major affiliated companies, reconfirming its existing business structure centered on two segments. - FY2022-Q1RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliated companies) during the cumulative first quarter of the fiscal year. There were also no changes among the major affiliated companies.」
The Company reported no material changes in its business activities or major affiliated companies, reconfirming its existing business structure. - FY2021RestatedAnnual report
「Centered on the Company, a pure holding company, the Group has two reportable segments: the API sales business and the pharmaceutical manufacturing and marketing business.」
The Group reconfirmed its business structure centered on two reportable segments. - FY2021-Q2RestatedAnnual report
「API sales business Pharmaceutical manufacturing and marketing business」
No material changes were reported in the business activities or major affiliated companies, and the two-reportable-segment structure continues to be presented. - FY2021-Q1RestatedAnnual report
「Reportable segments API sales business Pharmaceutical manufacturing and marketing business」
No material changes were reported in the business activities, and the two reportable segments, the API sales business and the pharmaceutical manufacturing and marketing business, continue to be presented. - FY2020-Q1RestatedAnnual report
「Reportable segments: API sales business; pharmaceutical manufacturing and marketing business」
The two reportable segments, the API sales business and the pharmaceutical manufacturing and marketing business, continue to be presented. - FY2019RestatedAnnual report
「Centered on the Company, a pure holding company, the Group has two reportable segments: the API sales business and the pharmaceutical manufacturing and marketing business.」
The Group reconfirmed its business structure centered on two segments. - FY2018First statedAnnual report
「Centered on the Company, a pure holding company, the Group has two reportable segments: the API sales business and the pharmaceutical manufacturing and marketing business.」
The disclosure presents the Group's reportable segments and business structure.